Works as intended

Third-Party Tested by Verum Analytics
Ipamorelin
Selective GHRP — stimulates natural growth-hormone release without cortisol or prolactin spikes.
Third-Party Tested by Verum Analytics

Albert's Verdict
Ipamorelin is the cleanest GHS-R1a agonist in the catalog — highly selective for pituitary release with minimal cortisol or prolactin signal. That selectivity is exactly what you want when isolating ghrelin-receptor mechanisms.
View COA✓ In stock - Ships same day
Arrives as lyophilized (powder) form
Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.
Product Description
Ipamorelin is a selective growth-hormone releasing peptide (GHRP) that stimulates natural pulsatile GH release from the pituitary gland. Its selectivity is what sets it apart — unlike older GHRPs, Ipamorelin does not meaningfully elevate cortisol, prolactin, or hunger, giving it the cleanest side-effect profile of any GH secretagogue.
Extensively researched for body composition, recovery, sleep quality, bone growth, and anti-aging applications. Most commonly paired with a GHRH such as CJC-1295 (No DAC) for a stronger, more synergistic GH pulse. For research use only. Not for human or veterinary consumption.
Technical Specifications
- Molecular Formula
- C38H49N9O5
- Molecular Weight
- 711.85 g/mol
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
Customer Reviews
Verified research purchases
My go-to source now
After trying a few different suppliers, I've settled on BioInfinity. The quality and service are consistently excellent. Highly recommend.
Verifiable quality
The ability to verify the COA on the testing lab's website is huge. This transparency sets BioInfinity apart from other suppliers.
Reliable and trustworthy
I needed a reliable source with good documentation. BioInfinity delivered on all fronts. Will definitely order again.
Great customer service
Had questions about reconstitution and storage. The support team responded quickly with helpful answers. Great experience.
Bulk discounts are great
The quantity discounts make this more affordable than other options. Quality is top notch and shipping is fast. Win-win.
Quality you can trust
The COAs and third-party testing documentation give me confidence. This is what professional suppliers should look like.
Best value around
When you factor in quality, documentation, and service, BioInfinity offers the best value. I've tried others - this is my standard now.
Fast shipping
Same-day shipping for orders before 2PM is clutch. Package arrived exactly when promised and in perfect condition.
Frequently Researched Together
Commonly studied alongside in laboratory settings
Research FAQ — Ipamorelin
Frequently asked questions about this compound for laboratory researchers.
What is Ipamorelin?+
How is Ipamorelin different from GHRP-2 or GHRP-6 in research literature?+
Is Ipamorelin commonly paired with CJC-1295 No DAC in research protocols?+
How should Ipamorelin be stored?+
Published research references
Peer-reviewed literature relevant to Ipamorelin research. Linked PubMed IDs open the original source.
- [1]Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol (1998) · PMID 9849822
- [2]Selective GH secretagogues: Ipamorelin pharmacology — Growth Horm IGF Res (2008) · PMID 18430761
- [3]Pulsatile GH release with ghrelin-mimetic peptides — J Endocrinol (2001) · PMID 11457741
Verified reviews — Ipamorelin
1 verified buyer
Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.
Learn More About This Peptide
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.
Ipamorelin — clinical & mechanistic profile
Ipamorelin is the first GHRP with GHRH-like selectivity, binding GHSR-1a (ghrelin receptor) to stimulate pulsatile GH release with EC50 = 1.3 nmol/L and Emax = 85% comparable to GHRP-6, but without ACTH/cortisol elevation even at >200-fold above GH ED50. Lower plasma clearance (5-fold slower than GHRP-6) with ~50% nasal bioavailability.
Research status
clinical investigational
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular weight
711.85 g/mol
Molecular formula
C38H49N9O5
Studied applications
- •Exceptional selectivity: no significant ACTH/cortisol elevation at >200-fold GH ED50, mirroring GHRH selectivity
- •GHRP-6 equivalent potency: EC50 = 1.3 ± 0.4 nmol/L, Emax = 85 ± 5% in rat pituitary; ED50 = 80 nmol/kg in vivo
- •Pulsatile GH release: dose-dependent peaks at 15-60 min, baseline by 180 min; synergistic with GHRH
- •Superior pharmacokinetics: 5-fold lower plasma clearance than GHRP-6, ~50% nasal bioavailability
- •GI-independent action: gastrectomy reduces GHRP-6 GH release 60-70%, suggesting gastric ghrelin component
Mechanisms of action
- •GHSR-1a agonism: selectively binds ghrelin receptor, confirmed via GHRP antagonist pharmacology (not GHRH pathway)
- •Pituitary somatotroph activation: directly stimulates GH-producing cells via Gq-protein/calcium signaling
- •Hypothalamic modulation: may upregulate GHRH mRNA in arcuate nucleus, downregulate somatostatin in periventricular nucleus
- •Calcium influx: triggers intracellular Ca2+ signaling from IP3-mediated stores for GH vesicle release
- •Pathway selectivity: minimal cross-talk to ACTH-releasing or prolactin-releasing pathways
- •Synergistic with GHRH: amplifies GH pulse through complementary cAMP (GHRH) and Ca2+ (ipamorelin) pathways
- •Not approved for human therapeutic use—research compound only
- •Clinical development for postoperative ileus discontinued
- •Short half-life (~2 hours) requires multiple daily administrations
- •GH elevation may affect glucose metabolism
- •Quality and purity of research compounds varies between sources
Peer-reviewed references
- Raun K, et al. — Ipamorelin selectivity and GH secretion (1998)PMID: 9849822View
- Ipamorelin vs. other GHRPs selectivity comparison (2001)PMID: 11452249View
- Pharmacokinetics and mechanism studiesPMID: 16352683View
- GHRPs hypothalamic GHRH/somatostatin modulationPMID: 8950613View
- Ipamorelin pharmacokinetics, nasal bioavailabilityPMID: 9879640View
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.